Bulletin
Investor Alert

Market Pulse Archives

April 26, 2021, 12:34 p.m. EDT

Reviva's stock jumps after experimental schizophrenia drug meets endpoint in Phase 2 clinical trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Reviva Pharmaceuticals Holdings Inc. (RVPH)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Reviva Pharmaceuticals Holdings Inc. /zigman2/quotes/204917861/composite RVPH +2.64% soared 76.6% in trading on Monday after the company said its experimental treatment for schizophrenia met the primary endpoint in a mid-stage clinical trial. Reviva said that the investigational therapy, brilaroxazine, met all safety endpoints and helped with "social functioning and cognition" in the randomized, placebo-controlled, double-blind Phase 2 clinical study. Reviva's stock is down 14.6% so far this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.08% is up 11.3%.

/zigman2/quotes/204917861/composite
US : U.S.: Nasdaq
$ 4.28
+0.11 +2.64%
Volume: 107,992
Sept. 21, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$55.83 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,354.19
-3.54 -0.08%
Volume: 1.91B
Sept. 21, 2021 5:12p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.